Sanofi TheraCys Shortage Prompts Merck To “More Than Double” Supply Of TICE BCG
This article was originally published in The Pink Sheet Daily
Executive Summary
In its latest attempt to get out in front of drug shortage problems, FDA’s announcement that Sanofi Pasteur’s bladder cancer drug TheraCys is unavailable due to manufacturing problems also notifies patients that Merck is stepping into the breach.